Analytical Data
-
Gene name
IL13RA2
- Application
-
Alternative Names
IL13RA2;IL13R;Interleukin-13 receptor subunit alpha-2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q14627
-
Expression Region
27-343aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSDTEIKVN PPQDFEIVDP GYLGYLYLQW QPPLSLDHFK ECTVEYELKY RNIGSETWKT IITKNLHYKD GFDLNKGIEA KIHTLLPWQC TNGSEVQSSW AETTYWISPQ GIPETKVQDM DCVYYNWQYL LCSWKPGIGV LLDTNYNLFY WYEGLDHALQ CVDYIKADGQ NIGCRFPYLE ASDYKDFYIC VNGSSENKPI RSSYFTFQLQ NIVKPLPPVY LTFTRESSCE IKLKWSIPLG PIPARCFDYE IEIREDDTTL VTATVENETY TLKTTNETRQ LCFVVRSKVN IYCSDDGIWS EWSDKQCWEG EDLSKKTLLR
-
Molecular Weight
40 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL13RA2, or Interleukin-13 Receptor Alpha 2, is a protein that has garnered significant attention in the field of cancer research due to its role in modulating immune responses and its association with tumor progression, particularly in glioblastomas and other malignancies. Expressed at high levels in certain tumor cells, IL13RA2 acts as a decoy receptor for interleukin-13 (IL-13), a cytokine involved in Th2 immune responses. The overexpression of IL13RA2 contributes to the tumor microenvironment's immune evasion, making it a promising target for therapeutic interventions. Recent studies have focused on the development of recombinant proteins and monoclonal antibodies that specifically target IL13RA2, aiming to harness the immune system for targeted cancer therapies. By utilizing strategies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies, researchers hope to enhance anti-tumor responses while minimizing damage to healthy tissues. The ongoing investigation into the structure, function, and potential of IL13RA2 as a biomarker or therapeutic target holds promise for improving treatment outcomes in cancers that exhibit elevated levels of this receptor. As a result, recombinant IL13RA2 proteins are being explored not only to elucidate the underlying mechanisms of cancer biology but also to advance innovative treatment modalities tailored to improve patient prognosis.
